Somerville Kurt F Invests $765,000 in Thermo Fisher Scientific Inc. $TMO

Somerville Kurt F purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,525 shares of the medical research company’s stock, valued at approximately $765,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Elyxium Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 1.9% during the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock valued at $613,000 after acquiring an additional 20 shares during the period. Revolve Wealth Partners LLC increased its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. lifted its stake in Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after acquiring an additional 20 shares during the last quarter. Confluence Wealth Services Inc. boosted its holdings in Thermo Fisher Scientific by 0.5% in the fourth quarter. Confluence Wealth Services Inc. now owns 4,292 shares of the medical research company’s stock worth $2,487,000 after purchasing an additional 22 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,985 shares of the medical research company’s stock worth $2,311,000 after acquiring an additional 22 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TMO. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. Barclays raised their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $628.24 on Friday. The firm has a market capitalization of $232.29 billion, a PE ratio of 33.79, a PEG ratio of 2.50 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99. The business’s 50 day moving average is $539.33 and its 200-day moving average is $508.86.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the prior year, the company posted $4.28 EPS. The business’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 4,608 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $586.12, for a total transaction of $2,700,840.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 63,493 shares of company stock valued at $37,657,681. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.